Current Tools and Methods in Molecular Dynamics (MD) Simulations for Drug Design

被引:72
作者
Hernandez-Rodriguez, Maricarmen [1 ]
Rosales-Hernandez, Martha C. [1 ]
Mendieta-Wejebe, Jessica E. [1 ]
Martinez-Archundia, Marlet [2 ]
Correa Basurto, Jose [2 ]
机构
[1] Inst Politecn Nacl, Lab Biofis & Biocatalisis, Escuela Super Med, Ciudad De Mexico, Mexico
[2] Inst Politecn Nacl, Lab Modelado Mol & Diseno Farmacos, Escuela Super Med, Ciudad De Mexico, Mexico
关键词
Drug design; Molecular Dynamics simulations; protein motions; drug discovery; docking studies; sampling several protein conformations; PROTEIN-LIGAND BINDING; FREE-ENERGY; FORCE-FIELD; CONFORMATIONAL ENSEMBLES; COMPUTATIONAL METHODS; NMR STRUCTURES; INHIBITORS; REFINEMENT; DOCKING; DISCOVERY;
D O I
10.2174/0929867323666160530144742
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Molecular Dynamics (MD) simulations is a computational method that employs Newton's laws to evaluate the motions of water, ions, small molecules, and macromolecules or more complex systems, for example, whole viruses, to reproduce the behavior of the biological environment, including water molecules and lipid membranes. Specifically, structural motions, such as those that are dependent of the temperature and solute/solvent are very important to study the recognition pattern of ligandprotein or protein-protein complexes, in that sense, MD simulations are very useful because these motions can be modeled using this methodology. Furthermore, MD simulations for drug design provide insights into the structural cavities required to design novel structures with higher affinity to the target. Also, the employment of MD simulations to drug design can help to refine the three-dimensional (3D) structure of targets in order to obtain a better sampling of the binding poses and more reliable affinity values with better structural advantages, because they incorporate some biological conditions that include structural motions compared to traditional docking procedures. This work analyzes the concepts and applicability of MD simulations for drug design because molecular structural motions are considered, and these help to identify hot spots, decipher structural details in the reported protein sites, as well as to eliminate sites that could be structural artifacts which could be originated from the structural characterization conditions from MD. Moreover, better free energy values for protein ligand recognition can also be obtained, and these can be validated under experimental procedures due to the robustness of the MD simulation methods.
引用
收藏
页码:3909 / 3924
页数:16
相关论文
共 85 条
  • [61] Three-dimensional structure and molecular dynamics studies of prorrenin/renin receptor: description of the active site
    Sanchez-Guerrero, E.
    Hernandez-Campos, M. E.
    Correa-Basurto, J.
    Lopez-Sanchez, P.
    Tolentino-Lopez, L. E.
    [J]. MOLECULAR BIOSYSTEMS, 2015, 11 (09) : 2520 - 2528
  • [62] Discovery of a novel binding trench in HIV integrase
    Schames, JR
    Henchman, RH
    Siegel, JS
    Sotriffer, CA
    Ni, HH
    McCammon, JA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (08) : 1879 - 1881
  • [63] Computational study of the mechanism and the relative free energies of binding of anticholesteremic inhibitors to squalene-hopene cyclase
    Schwab, Fabienne
    van Gunsteren, Wilfred F.
    Zagrovic, Bojan
    [J]. BIOCHEMISTRY, 2008, 47 (09) : 2945 - 2951
  • [64] How Does a Drug Molecule Find Its Target Binding Site?
    Shan, Yibing
    Kim, Eric T.
    Eastwood, Michael P.
    Dror, Ron O.
    Seeliger, Markus A.
    Shaw, David E.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2011, 133 (24) : 9181 - 9183
  • [65] Anton, a special-purpose machine for molecular dynamics simulation
    Shaw, David E.
    Deneroff, Martin M.
    Dror, Ron O.
    Kuskin, Jeffrey S.
    Larson, Richard H.
    Salmon, John K.
    Young, Cliff
    Batson, Brannon
    Bowers, Kevin J.
    Chao, Jack C.
    Eastwood, Michael P.
    Gagliardo, Joseph
    Grossman, J. P.
    Ho, C. Richard
    Ierardi, Douglas J.
    Kolossvary, Istvan
    Klepeis, John L.
    Layman, Timothy
    Mcleavey, Christine
    Moraes, Mark A.
    Mueller, Rolf
    Priest, Edward C.
    Shan, Yibing
    Spengler, Jochen
    Theobald, Michael
    Towles, Brian
    Wang, Stanley C.
    [J]. COMMUNICATIONS OF THE ACM, 2008, 51 (07) : 91 - 97
  • [66] Exploring the Potential binding Sites of Some Known HDAC Inhibitors on Some HDAC8 Conformers by Docking Studies
    Sixto-Lopez, Yudibeth
    Gomez-Vidal, Jose A.
    Correa-Basurto, Jose
    [J]. APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2014, 173 (07) : 1907 - 1926
  • [67] Computational Methods in Drug Discovery
    Sliwoski, Gregory
    Kothiwale, Sandeepkumar
    Meiler, Jens
    Lowe, Edward W., Jr.
    [J]. PHARMACOLOGICAL REVIEWS, 2014, 66 (01) : 334 - 395
  • [68] Recent advances in computer-aided drug design
    Song, Chun Meng
    Lim, Shen Jean
    Tong, Joo Chuan
    [J]. BRIEFINGS IN BIOINFORMATICS, 2009, 10 (05) : 579 - 591
  • [69] Protein Flexibility and Ligand Recognition: Challenges for Molecular Modeling
    Spyrakis, Francesca
    BidonChanal, Axel
    Barril, Xavier
    Javier Luque, F.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (02) : 192 - 210
  • [70] Investigation of differences in the binding affinities of two analogous ligands for untagged and tagged p38 kinase using thermodynamic integration MD simulation
    Sun, Ying-Chieh
    Hsu, Wen-Chi
    Hsu, Chia-Jen
    Chang, Chia-Ming
    Cheng, Kai-Hsiang
    [J]. JOURNAL OF MOLECULAR MODELING, 2015, 21 (11)